MESO:NASDAQ; MSB:ASE; MBLTY:OTCPK

Mesoblast Ltd.

Mesoblast Ltd. is a clinical development company leveraging its proprietary core adult stem cell technologies, which include the Mesenchymal Precursor Cell (MPC) and culture-expanded Mesenchymal Stem Cell (MSC) platform technologies, Dental Pulp Stem Cells and expanded Hematopoietic Stem Cells. The company's cardiovascular and neurologic product pipeline is being developed in partnership with Teva Pharmaceutical Industries Ltd. Mesoblast Ltd's subsidiaries include Mesoblast Inc., Mesoblast International SA, Mesoblast Australia Pty Ltd and Mesoblast UK Ltd.
MESO:NASDAQ MSB:ASE

Expert Comments:

Katherine Genis, Edison Investment Research (3/24/16)
"In September 2015 Mesoblast Ltd. announced Phase 2 trial results for MPC-150-IM, showing greatest cardioprotective effect in patients with advanced heart failure. Clinical data from two Phase 3 studies will support regulatory approval; interim analysis of the first trial is anticipated in Q2/16."

Jason Kolbert, Maxim Group (3/17/16)
"The strength in Mesoblast Ltd.'s shares appears to be a result of an artificially depressed valuation triggered by the U.S. NASDAQ listing. Given the success in Japan and the multiple catalysts ahead, as well as other recent success in the competitive landscape of cell therapy, we believe the rebound in valuation is justified."

Henry McCusker, RegMed Investors (2/25/16)
"A Mesoblast Ltd. licensee launched the first allogeneic cell therapy product in Japan for the treatment of acute graft-versus-host disease in children and adults. . .Temcell is the first allogeneic cell therapy to be fully approved in Japan. The Japanese government's National Health Insurance set reimbursement for Temcell at 868,680 yen (approximately $7,700) per bag of 72M cells."

Kevin DeGeeter, Ladenburg Thalmann (2/23/16)
"Mesoblast Ltd. presented results from 241 patients enrolled onto Protocol 275, an expanded access study of remestemcel-L for steroid-refractory acute graft-versus-host disease. . .on net, the results give us increased confidence the ongoing Phase 3 study of remestemcel-L in 60 children will be positive. The company expects to present interim topline data in Q3/16 with complete data in H1/17."

Jason Kolbert, Maxim Group (2/22/16)
"Mesoblast Ltd. announced results for MSC-100-IV that showed clinically meaningful responses and significantly increased survival in children with steroid-refractory acute graft-versus-host disease (aGVHD). . .key results in the 241 children with steroid-refractory aGVHD were: an overall response rate of 65% was seen at day 28 after treatment with MSC-100-IV, and a response rate of 81% was seen when MSC-100-IV was used as frontline therapy following steroid failure."

Jason Kolbert, Maxim Group (2/16/16)
"Mesoblast Ltd.'s allogeneic cell therapy product, MPC-300 IV, is being evaluated in a double-blind, randomized, placebo-controlled, two-dose escalating trial in the U.S. . .the data look amazing in our view, especially when we consider that all the cell infusions were well tolerated with no cell-related adverse events. In other words we believe there is no risk but clearly activity."

More Expert Comments

Experts Following This Company

Kevin DeGeeter, Director, Equity Research Analyst – Ladenburg Thalmann
Katherine Genis, Analyst – Edison Investment Research
Jason Kolbert, Senior Analyst – Maxim Group
Jason McCarthy, Analyst – Maxim Group
Henry McCusker, Founder and Director of Research – Scimitar Equity
Henry McCusker RegMed Investors
Marcel Wijma, Analyst – The Daily Molecule (Van Leeuwenhoeck Research), Van Leeuwenhoeck Research

The information provided above is from analysts, newsletters, the company and other contributors.

Mesoblast Ltd. is a former billboard advertiser of Streetwise Reports. The company's advertising fees paid for Streetwise Reports to create this "Investor Summary Page," to which links were placed on Streetwise Reports' websites and newsletters. Streetwise Reports did not accept stock for the payment of fees. See disclaimer for more details.

The company description, investing highlights and catalyst calendar on this page were prepared by the company. The Expert Comments and Experts Following This Company sections of this page are compiled by Streetwise Reports. There may be other information about the company that is not placed on this page. Streetwise Reports does not guarantee the accuracy or thoroughness of the information contained on this page.

Streetwise Reports does not provide investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security.Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.

Readers should conduct their own research for all information publicly available concerning the company.